Regulatory Story
Go to market news section View chart   Print

Analyst & Investor Briefing

Released 07:00 09-Oct-2013

RNS Number : 0694Q
Hutchison China Meditech Limited
09 October 2013




Hutchison China MediTech Limited ("Chi-Med")



Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing



London: Wednesday, 9 October 2013: Chi-Med today announces that further to the announcement made on 3 October 2013 relating to the briefing for investors and analysts to be held at The Brewery (The James Watt room), 52 Chiswell Street, London, EC1Y 4SD today at 9:30 am, it wishes to state that no new material information will be disseminated at the briefing.









   Christian Hogg, CEO

Telephone:      +852 2121 8200

   Panmure Gordon (UK) Limited
   Richard Gray
   Andrew Potts
   Grishma Patel


Telephone:      +44 20 7886 2500

   Citigate Dewe Rogerson
   Anthony Carlisle
   David Dible

Telephone:      +44 20 7638 9571
Mobile:             +44 7973 611 888
Mobile:             +44 7967 566 919



Notes to Editors


About HMP


HMP is a novel drug R&D division focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.


HMP is majority owned by Chi-Med.  For more information, please visit:



About Chi-Med


Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.


Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.  For more information, please visit:

This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Analyst & Investor Briefing - RNS